Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 2, 1996, Pages 102-108

  Schwendener, R A ^a   Horber, D H ^a   Odermatt, B ^a   Schott, H ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Lipophilic AraC derivatives; Liposomes; Oral activity; Pharmacokinetics; Toxicity

Indexed keywords

CYTARABINE; CYTARABINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; LEUKEMIA L 1210; MOUSE; PHARMACOKINETICS; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CYTARABINE; DRUG CARRIERS; FEMALE; HEMOLYSIS; HUMANS; LEUKEMIA L1210; LIPOSOMES; MICE; MICE, INBRED ICR; NEOPLASM TRANSPLANTATION; TISSUE DISTRIBUTION;

EID: 0030068082     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01226267     Document Type: Article

References (26)

1. Allen TM (1989) Stealth-liposomes: avoiding reticuloendothelial uptake. In: Lopez-Berenstein G, Fidler IJ (eds) Liposomes in the therapy of infectious diseases and cancer. Liss, New York, pp 405-415
2. Braess, J, Ramsauer B, Hiddemann W, Burk K, Schüssler M, Keye S, Schleyer H (1994) Pharmacokinetics of YNK01 (fosteabine) the oral derivative of cytosinearabinoside. Ann Oncol S5:173
3. Chabner BA (1990) Cytidine analogues. In: Chabner BA, Collins JM (eds) Cancer chemotherapy, principles and practice. Lippincott, Philadelphia, pp 154-179
4. Hellström-Lindberg E, Robert KH, Gahrton G, Lindberg G, Forsblom AM, Kock Y, Ost A (1994) Low-dose ara-C in myclodysplastic syndromes (MSD) and acute leukaemia following MSD: proposal for a predictive model. Leuk Lymphoma 12:343-351
5. 50 test. Food Chem Toxicol 28:469-482
6. Ho DHW, Frei E (1971) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine. Clin Pharmacol Ther 12:944-954
7. Ho DH, Carter CJ, Loo TL, Abbott RL, McBride CM (1975) Pharmacologic studies of cyclocytidine and arabinosylcytosine in dogs. Drug Metab Dispos 3:309-313
8. Hope MJ, Bally MB, Webb G, Cullis PR (1985) Production of large unilamellar vesicles by a rapid procedure, characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812:55-65
9. 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J Pharm Pharmacol 47:282-288
10. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer 71:957-962
11. 4-hexadecyl-1-β-D-arabinofuranosyl-cytosine, a new lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br J Cancer (in press)
12. Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ (1992) Evolution of treatment for acute myelogenous leukaemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukaemia 6 [Suppl 2]: 78-80
13. Kodama K, Morozumi M, Saitoh K, Kuninaka A, Yoshino, H, Sancyoshi M (1989) Antitumor activity and pharmacology of 1-β-D-arabinofuranosyleytosine-5′-stearylphosphate: an orally active derivative of 1-β-D-arabinofuranosylcytosine. Jpn J Cancer Res 80:679-685
14. Miller KB, Kim K, Morrison FS, Winter JN, Bennett JM, Neiman RS, Head DR, Cassileth PA, O'Connell MJ, Kyungmann K (1992) The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase III study. Ann Haematol 65:162-168
15. Neil GL, Moxley TE, Manak RC (1970) Enhancement by tetrahydrouridine of 1-β-D-arabinofuranosylcytosine (Cytarabine) oral acivity in L1210 leukemic mice. Cancer Res 30:2166-2172
16. 4-palmitoyl-1-β-D-arabinofuranosylcytosine. Cancer Chemother Pharmacol 17:161-164
17. Ohno R, Tatsumi N, Hirano M, Imai K, Mizoguchi H, Nakamura T, Kosaka M, et al. (1991) Treatment of myelodysplastic syndromes with orally administred 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate. Oncology 48:451-455
18. 4-acyl and 2.2′-anhydro-3′-O-acylderivatives as potential prodrugs. J Med Chem 25:171-178
19. Rubas W, Supersaxo A, Weder HG, Hartmann HR, Hengartner H, Schott H, Schwendener RA (1986) Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int J Cancer 37:149-154
20. Schott H, Häussler MP, Schwendener RA (1994) Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Wirkung im L1210 Läukemiemodell der Maus. Liebigs Ann Chem 465
21. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. Int J Cancer 52:1-4
22. 4t;-octadecyl-1-β-D-arabinofuranosylcytosine in liposomal preparations. J Liposome Res 5:27-47
23. Thomson ABR, Schoeller C, Keelan M, Smith L, Clandinin MT (1993) Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol 71:531-555
24. 4-stearoyl-1-β-D-arabinofuranosylcytosine as new antitumor agent. In: Grassi JD (ed) Current chemotherapy and infectious disease. American Society of Microbiology, Washington, DC, pp 1591-1593
25. Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T (1994) Clinical pharmacology of 1-β-D-arabinofuranosylcytosine-5′-stearylphosphate, an orally administred long-acting derivative of low-dose 1-β-D-arabinofuranosylcytosine. Cancer Res 54:109-113
26. 4-substituted derivatives of 1-β-D-arabinofuranosyl cytosine and -5-fluorocytosine. J Med Chem 11:144-148